Last reviewed · How we verify
Phytotherapy
Phytotherapy is a Small molecule drug developed by Pierre Fabre Medicament. It is currently in Phase 2 development. Also known as: Alpha-blockers.
Phytotherapy, also known as herbal medicine, is the study of medicinal plants and their use in traditional medicine, with a focus on pharmacognosy. Phytotherapy has been studied in various clinical trials for conditions such as anxiety, pain, postoperative nausea and vomiting, gynecological disease, and cancer, often in combination with other interventions like aromatherapy and music concert.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Phytotherapy |
|---|---|
| Also known as | Alpha-blockers |
| Sponsor | Pierre Fabre Medicament |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety of Shoulder Chuna on in Patients With Shoulder Pain Caused by Traffic Accidents (NA)
- Aromatherapy for Reducing Labor Pain (NA)
- Evaluation of the Therapeutic Approach of Aromatherapy by Olfaction of Essential Oils in Association With Hypnosis in the Management of Patients Followed for Cancer
- Developing a Community Support Program to Help People Quit Smoking. (NA)
- Humidified Forest Oils for Immune System Recovery in Stage I-III Breast or Prostate Cancer (NA)
- The Efficacy and Safety of Shoulder Motion Style Acupuncture Treatment (MSAT) on in Patients With Shoulder Pain Caused by Traffic Accidents (NA)
- EFFECTS of MORINGA OLEIFERA LEAF POWDERS on HEMATOLOGICAL PROFILES IN PREGNANT WOMEN WITH IRON DEFICIENCY ANAEMIA (NA)
- Prospective AnalysiS of Self medIcation With phytOtherapy in Nephropatic Patients. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phytotherapy CI brief — competitive landscape report
- Phytotherapy updates RSS · CI watch RSS
- Pierre Fabre Medicament portfolio CI
Frequently asked questions about Phytotherapy
What is Phytotherapy?
Who makes Phytotherapy?
Is Phytotherapy also known as anything else?
What development phase is Phytotherapy in?
Related
- Manufacturer: Pierre Fabre Medicament — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Alpha-blockers
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing